Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves’ Disease Patients
Authors' conclusion
Neutropenia occurred significantly more often under CBZ than MMI.
Study context
- Population
- Pediatric patients with Graves' disease (GD) treated with ATD (fT4 >25 pmol/L, TSH <0.05 mlU/mL, TSHRAbs >2.5 IU/L)
- Participants
- 161 patients
- Exposure
- Carbimazole (CBZ) vs MMI in pediatric GD
- CBZn = 40
- MMIn = 110reference
- Outcome
- Neutropenia (ANC <1800/µL) during ATD
Main finding
As reported in the abstract
Neutropenia during ATD
P = 0.001
- Became neutropenic while receiving ATD (overall)
- 38 (23.6%)
Observational data: associations, not effects.
Further findings
| Outcome | CBZ | MMI | P value |
|---|---|---|---|
| Minimum ANCLower with CBZ | 1971 ± 1008 /µL | 2546 ± 959 | P = 0.004 |
Neutropenia at diagnosis
- Patients with neutropenia at diagnosis, without further deterioration under ATD
- 9 of 161
- Absolute neutrophil count (ANC) at diagnosis in this subgroup
- 1348/µL ± 250
- fT3 at diagnosis: pre-treatment neutropenia vs developed neutropenia
- 31.45 pmol/L ± 3.99 vs 26.29 pmol/L ± 12.96; p = 0.07
- fT3 at diagnosis: pre-treatment neutropenia vs no neutropenia
- 31.45 pmol/L ± 3.99 vs 23.12 pmol/L ± 13.7; p = 0.003
Age and neutropenia
- Patients with neutropenia were significantly younger
- P = 0.031
Safety
Neutropenia and agranulocytosis under ATD
- ANC in patients who became neutropenic
- 1479/µL ± 262
- Mean time to neutropenia
- 551.8 (range: 10-1376) days
- Agranulocytosis with emergency thyroidectomy
- 2 of 38
Original publication
Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves’ Disease Patients. Thyroid. Published 8 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →